Viagra, the little blue pill, has been a household name for more than a generation. And now women's sexual health is finally entering the long-overdue conversation. The FDA recently approved the use ...

The FDA has expanded its approval of a libido-boosting drug to postmenopausal women. Xvision/Getty Images Postmenopause refers to the time period after the person finishes menopause and no longer has ...

Addyi, sometimes referred to as “female Viagra,” is now approved for use to treat low sex drive in postmenopausal women. MoMo Productions/Getty Images The Food and Drug Administration (FDA) expanded ...

Add Yahoo as a preferred source to see more of our stories on Google. Addyi is the brand name for a prescription drug that treats hypoactive sexual desire disorder (HSDD), the medical term for low sex ...

In the often unspoken world of female sexual health, a revolution has started, and it began with the introduction of a unique medication called Addyi. Traditionally, when we think of sexual ...

Flibanserin, marketed as Addyi, is the first FDA-approved drug for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Clinical trials show it can modestly increase sexual desire ...

RALEIGH, N.C., Jan. 29, 2026 /PRNewswire/ -- Sprout Pharmaceuticals today announced that Addyi® has been named "Best Prescription for Low Libido" in the 2026 Oprah Daily Menopause O-wards, one of the ...

INDIANAPOLIS (WISH) — This week, the Food and Drug Administration approved Addyi, the first medication for low libido in women younger than 65 years of age. Low libido affects 1 in 8 postmenopausal ...

A new documentary, 'The Pink Pill: Sex, Drugs and Who Has Control,' explores the fight to bring the women’s sexual health pill, Addyi, to market Addyi; Catalyst Works The new documentary, The Pink ...

When it comes to a woman's health, Addyi is a vital medication. It can provide relief from the symptoms of female sexual dysfunction and help women to enjoy sex again. With the right insurance ...

The US Food and Drug Administration (FDA) has warned Sprout Pharmaceuticals for the second time concerning its promotion of its hypoactive sexual desire disorder (HSDD) drug Addyi. The agency also ...